Detecting and monitoring human leukocyte antigen–specific antibodies

Leffell, Mary S.

doi:10.1016/j.humimm.2008.06.013

Cited by 64 publications

(42 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, recently developed solidphase immunoassays, including the Luminex single antigen assays, allow the accurate identification and quantification of specific HLA antibodies, 22 which enable the comparison of the specificity of HLA antibodies between donors and patients. To date, only one report by Hatakeyama et al 23 demonstrated similar specificities between HLA antibodies that emerged in two patients and those found in their donors.…”

Section: Discussionmentioning

confidence: 99%

Donor-derived HLA antibody production in patients undergoing SCT from HLA antibody-positive donors

Taniguchi

Yoshihara

Maruya³

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Donor-derived HLA antibody production in patients undergoing SCT from HLA antibody-positive donors

Taniguchi

Yoshihara

Maruya³

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

“…[6][7][8][9] Furthermore, novel solidphase immunoassays, including Luminex single-Ag assays that use purified preparations of molecules corresponding to a single HLA Ag, allow accurate identification and quantification of specific HLA antibodies. 10 Recent studies indicate that the risk for both Ab-mediated rejection and graft loss after kidney transplantation directly correlate with peak levels of donor-specific HLA antibodies (DSA), as measured by Luminex single-Ag assays. 11 In this study, we examined HLA antibodies as part of the pretransplant work-up for patients undergoing haploidentical SCT (haplo-SCT).…”

Section: Introductionmentioning

confidence: 99%

Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT

Yoshihara

Maruya²,

Taniguchi

et al. 2011

Bone Marrow Transplant

196

201

View full text Add to dashboard Cite

A role of donor-specific HLA antibodies (DSA) in graft failure after SCT has been suggested, but the relevance of DSA in unmanipulated haploidentical SCT (haplo-SCT) remains unknown. We prospectively examined HLA antibodies using the Luminex-based single Ag assay for 79 adult patients undergoing unmanipulated haplo-SCT. Among them, 16 (20.2%) were HLA Ab-positive, including five patients with antibodies not corresponding to donor HLA Ags and 11 DSA-positive patients. Of the 11 DSA-positive patients, five received treatments to decrease DSA levels, including two, who received plasma exchange and rituximab, two who received platelet transfusions from healthy-related donors having DSAcorresponding HLA Ags and one who received bortezomib. Platelet transfusion was the most simple and effective treatment option for class I DSA. The cumulative incidence of neutrophil recovery was significantly lower in pretransplant (post-treatment) DSA-positive patients than in DSA-negative patients (61.9 vs 94.4%, P ¼ 0.026). Notably, three of five patients with high levels of DSA had graft failure. Donors should be selected on the basis of an evaluation of HLA antibodies. If haplo-SCT from donors with HLA Ags that correspond to high levels of DSA must be performed, then recipients should be treated for DSA to improve the chances of successful donor engraftment.

show abstract

“…New solid-phase antibody detection technologies can better identify HLA-specific alloantibodies and are more sensitive than cytotoxicity testing and flow cytometry. [8][9][10][11] Using these methods, it may be possible to predict alloreactivity against HLA mismatches for unrelated donor recipient pairs before transplantation. Takanashi et al have reported that virtual cross-match-detected DSAs predict graft failure of unrelated umbilical cord blood transplantation.…”

Section: Introductionmentioning

confidence: 99%

The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure

Spellman

Bray

Rosen-Bronson

et al. 2010

Blood

254

179

View full text Add to dashboard Cite

Donor-directed human leukocyte antigen (HLA)-specific allo-antibodies (DSAs) cause graft failure in animal models of hematopoietic stem cell transplantation (HCT). Archived pretransplantation sera from graft failure patients (n ‫؍‬ 37) and a matched case-control cohort (n ‫؍‬ 78) were tested to evaluate the role of DSAs in unrelated donor HCT. Controls were matched for disease, disease status, graft type, patient age, and transplantation year.Patients had acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome; 98% received myeloablative conditioning regimens 100% received T-replete grafts, 97% received marrow, 95% HLA-mismatched, and 97% received calcineurin-based graft-versus-host disease prophylaxis. Among the 37 failed transplantations, 9 (24%) recipients possessed DSAs against HLA-A, B, and/or DP, compared with only 1 (1%) of 78 controls. Therefore, the presence of DSAs was significantly associated with graft failure (odds ratio ‫؍‬ 22.84; 95% confidence interval, 3.57-ؕ; P < .001). These results indicate that the presence of pretransplantation DSAs in recipients of unrelated donor HCT is associated with failed engraftment and should be considered in HCT donor selection. (Blood. 2010; 115(13):2704-2708)

show abstract

Detecting and monitoring human leukocyte antigen–specific antibodies

Cited by 64 publications

References 76 publications

Donor-derived HLA antibody production in patients undergoing SCT from HLA antibody-positive donors

Donor-derived HLA antibody production in patients undergoing SCT from HLA antibody-positive donors

Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT

The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure

Contact Info

Product

Resources

About